Secondary Stroke Prevention in Atrial Fibrillation: New Insights Into an Old Problem.
作者信息
Gurol M Edip
机构信息
From the Department of Neurology, Massachusetts General Hospital, Boston.
出版信息
Stroke. 2018 Jun;49(6):1315-1317. doi: 10.1161/STROKEAHA.118.021262. Epub 2018 May 8.
Abstract
摘要
相似文献
1
Secondary Stroke Prevention in Atrial Fibrillation: New Insights Into an Old Problem.
Stroke. 2018 Jun;49(6):1315-1317. doi: 10.1161/STROKEAHA.118.021262. Epub 2018 May 8.
2
Heartbeat: Left atrial appendage occlusion for stroke prevention.
Heart. 2017 Jan 15;103(2):89-90. doi: 10.1136/heartjnl-2016-311056.
3
Left Atrial Appendage Occlusion for Stroke Prevention in Nonvalvular Atrial Fibrillation.
J Am Heart Assoc. 2021 Nov 2;10(21):e022274. doi: 10.1161/JAHA.121.022274. Epub 2021 Oct 20.
4
Stroke prevention in nonvalvular atrial fibrillation.
Tex Heart Inst J. 2011;38(4):350-2.
5
Left atrial appendage closure: An emerging option in atrial fibrillation when oral anticoagulants are not tolerated.
Cleve Clin J Med. 2015 Mar;82(3):167-76. doi: 10.3949/ccjm.82a.14117.
6
Left Atrial Appendage Occlusion for The Unmet Clinical Needs of Stroke Prevention in Nonvalvular Atrial Fibrillation.
Mayo Clin Proc. 2019 May;94(5):864-874. doi: 10.1016/j.mayocp.2018.09.025. Epub 2019 Apr 5.
7
Meta-analysis of Left Atrial Appendage Closure Versus Anticoagulation in Patients With Atrial Fibrillation.
Am J Cardiol. 2020 Oct 1;132:181-182. doi: 10.1016/j.amjcard.2020.07.022. Epub 2020 Jul 21.
8
Left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation: ready for the prime time?
Expert Rev Cardiovasc Ther. 2013 Dec;11(12):1587-9. doi: 10.1586/14779072.2013.846216.
9
Left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation.
Expert Rev Cardiovasc Ther. 2015;13(8):907-14. doi: 10.1586/14779072.2015.1057123. Epub 2015 Jun 12.
10
Percutaneous closure of the left atrial appendage for stroke prevention in atrial fibrillation: an alternative to lifelong anticoagulation?
Crit Care Nurs Q. 2015 Oct-Dec;38(4):371-84. doi: 10.1097/CNQ.0000000000000081.
引用本文的文献
1
Outcomes of non-vitamin K oral anticoagulants for secondary prevention in ischemic stroke with atrial fibrillation.
Sci Rep. 2024 Apr 29;14(1):9838. doi: 10.1038/s41598-024-60660-z.
2
Updates on Prevention of Cardioembolic Strokes.
J Stroke. 2018 May;20(2):180-196. doi: 10.5853/jos.2018.00780. Epub 2018 May 31.
本文引用的文献
1
[The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary].
Kardiol Pol. 2018;76(9):1283-1298. doi: 10.5603/KP.2018.0180.
2
Cost-Effectiveness of Left Atrial Appendage Closure With the WATCHMAN Device Compared With Warfarin or Non-Vitamin K Antagonist Oral Anticoagulants for Secondary Prevention in Nonvalvular Atrial Fibrillation.
Stroke. 2018 Jun;49(6):1464-1470. doi: 10.1161/STROKEAHA.117.018825. Epub 2018 May 8.
3
Nonpharmacological Management of Atrial Fibrillation in Patients at High Intracranial Hemorrhage Risk.
Stroke. 2018 Jan;49(1):247-254. doi: 10.1161/STROKEAHA.117.017081. Epub 2017 Dec 4.
4
Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial.
J Am Coll Cardiol. 2014 Jul 8;64(1):1-12. doi: 10.1016/j.jacc.2014.04.029.
5
Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial.
Lancet. 2009 Aug 15;374(9689):534-42. doi: 10.1016/S0140-6736(09)61343-X.
Zotero 插件